<DOC>
	<DOCNO>NCT00753714</DOCNO>
	<brief_summary>The primary objective study demonstrate improvement Progression-Free Survival ( PFS ) combination vandetanib plus gemcitabine compare gemcitabine plus placebo chemonaïve ( include adjuvant regimen ) patient age ≥ 70 year advance NSCLC .</brief_summary>
	<brief_title>Zactima Non Small Cell Lung Cancer ( NSCLC ) ELderly Patients In Combination With Versus Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologic cytologic confirmation advance NSCLC ( stage IIIB supraclavicular lymph node metastases pleural effusion stage IV ) entry study One measurable lesion least 10 mm long diameter ( LD ) spiral CT scan 20 mm conventional technique accord RECIST criterion Chemotherapynaïve ( prior chemotherapy adjuvant set complete 3 month trial entry accept ) . Female male age 70 year Patients must receive prior anticancer therapy except adjuvant set Inadequate endorgan function Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial Significant cardiovascular event ( e.g . myocardial infarction , superior vena cava [ SVC ] syndrome , New York Heart Association [ NYHA ] classification heart disease ³2 ) within 3 month entry , presence cardiac disease opinion History arrhythmia QTc Bazett 's correction unmeasurable ≥ 480 msec screening ECG</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>VANDETANIB</keyword>
	<keyword>ZACTIMA</keyword>
	<keyword>ADVANCED</keyword>
	<keyword>NSCLC</keyword>
	<keyword>LUNG CANCER</keyword>
	<keyword>ELDERLY PATIENTS</keyword>
	<keyword>GEMCITABINE</keyword>
	<keyword>PHASE II</keyword>
	<keyword>RANDOMIZED</keyword>
	<keyword>DOUBLE-BLIND</keyword>
	<keyword>histologically cytologically-confirmed advanced ( stage IIIB supraclavicular lymph node metastases pleural effusion stage IV ) NSCLC</keyword>
</DOC>